Results 31 to 40 of about 443 (50)

First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population [PDF]

Sajid Iqbal, Hani Sabbour, Tanveer Ashraf, Raúl D. Santos, Adam Buckley   +4 more
openalex   +1 more source

6 MONTHLY INCLISIRAN AND ATHEROGENIC LIPOPROTEIN REDUCTIONS IN ORION-11

, 2020
Kausik K. Ray, David Kallend, Wolfgang Köenig, Lawrence A. Leiter, Frederick J. Raal, Scott Wright, Peter Wijngaard, John J.P. Kastelein   +7 more
openalex   +1 more source

The Safety Profile of Inclisiran in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis [PDF]

Maisha Maliha, Vikyath Satish, Sriram Sunil Kumar, Kuan‐Yu Chi, Nishat Shama, Amrin Kharawala, Gustavo Duarte, Weijia Li, Sanjay Purkayastha, Shaunak Mangeshkar, Pawel Borkowski, Eleonora Gashi, Supreeti Behuria   +12 more
openalex   +1 more source

The Efficacy and Safety of Inclisiran for Low-Density Lipoprotein (LDL) in Patients With Atherosclerotic Cardiovascular Disease (ASCVD): A Systematic Review of Randomized Controlled Trials

Hyder Osman Mirghani, Bandar H Albalawi, Mohammed S. Alshehri, Waseem M Almalawi, Sumaya Abdulallah Alanezi, Mahmoud Alarki, Abdullah A Alyahya, Sultan Alshaman, Mariam S Shaman, Abeer AlAnazi   +9 more
openalex   +1 more source

Long-term cardiovascular safety of Inclisiran: a pooled analysis of phase 3 randomized trials.

Paschalis Karakasis, Dimitrios Patoulias, Fotios Barkas, Panagiotis Theofilis, Haralampos Milionis, Michael Doumas, George Kassimis, Konstantinos Tsioufis, Nikolaos Fragakis   +8 more
openalex   +1 more source

The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis

Wenjing Zhou, Zhuoru Liang, Xiaohuan Lou, Nansong Wang, Xinyu Liu, Ruoxi Li, Pearl Pai   +6 more
openalex   +1 more source

A jelentős mértékű, hosszú távú lipidcsökkentés biztonsága : Fókuszban az inclisiran, Braunwald víziójával

László Márk
openalex   +1 more source

Inclisiran Usage in Very High-Risk Patients with Dyslipidemia Resistant to Statins and Ezetimibe Therapy

Yevhen Yu. Marushko, Boris Mankovsky, Anastasiia A. Levadska   +2 more
openalex   +2 more sources

THE POTENTIAL DANGER TO ASCVD RISK REDUCTION: A RARE CASE OF INCLISIRAN INDUCED VASCULITIS

Sumair Ozair
openalex   +1 more source

Inclisiran in India: A Game-changer for Dyslipidemia Management

A.N. Patnaik
openalex   +1 more source